radotinib

{{Short description|Chemical compound}}

{{Drugbox

| drug_name =

| IUPAC_name = 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide

| image = Radotinib.svg

| width = 300

| alt =

| caption =

| tradename = Supect

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 926037-48-1

| ATCvet =

| ATC_prefix = None

| ATC_suffix =

| PubChem = 16063245

| DrugBank =

| ChemSpiderID = 17222861

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = I284LJY110

| C=27 | H=21 | F=3 | N=8 | O=1

| StdInChI = 1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)

| StdInChIKey = DUPWHXBITIZIKZ-UHFFFAOYSA-N

| smiles = Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1

}}

Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML){{cite journal

| journal = Annual Reports in Medicinal Chemistry | volume = 48 | pages = 523–524 | title = To Market, To Market - 2012: Radotinib (Anticancer) | vauthors = Bronson J, Black A, Dhar TG, Ellsworth BA, Merritt JR | doi=10.1016/b978-0-12-417150-3.00028-4| year = 2013 | isbn = 9780124171503 }} with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.

Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea{{Cite web | url=http://www.ilyang.co.kr/english/rnd/rnd03.asp | title=Il-Yang Pharmaceutical}} and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea.{{cite web | vauthors = Yoon EK | date = 23 October 2012 |url=http://www.dailypharm.com/Users/News/EnglishNews.html?NewsID=3108&nStart=1023&mode=&searchValue= |title= Daewoong will market Ilyang's new leukemia drug |work = Daily Pharm News |url-status=dead |archive-url=https://web.archive.org/web/20160303221246/http://www.dailypharm.com/Users/News/EnglishNews.html?NewsID=3108&nStart=1023&mode=&searchValue= |archive-date=2016-03-03}} Radotinib completed a multi-national Phase II clinical trial study in 2012{{cite journal | vauthors = Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW | display-authors = 6 | title = Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors | journal = Haematologica | volume = 99 | issue = 7 | pages = 1191–1196 | date = July 2014 | pmid = 24705186 | pmc = 4077080 | doi = 10.3324/haematol.2013.096776 }} and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication.{{ClinicalTrialsGov|NCT01511289|A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase}} Its mechanism of action involves inhibition of the Bcr-Abl tyrosine kinase and of platelet-derived growth factor receptor (PDGFR).{{Cite web | url = http://www.cancer.gov/drugdictionary?cdrid=723999 | work = NCI Drug Dictionary | publisher = National Cancer Institute | title = Radotinib hydrochloride | date = 2011-02-02 }}